Founded in 2001 and headquartered in Cologne, Germany, Axiogensis is one of a small number of companies specializing in induced pluripotent stem cell (iPSC) products. The company also has an American subsidiary that was founded in 2014 and is located in Philadelphia, Pennsylvania. Since its launch, the company has grown into a market leader for in vitro models of healthy and diseased cell types and tissue. [Read more…]
Cynata Announces Japanese Patent Office to Grant Patent for Cymerus™ MSC Technology
Cynata Therapeutics, a stem cell and regenerative medicine company listed on the Australian stock exchange (ASX: CYP), released major news today that the Japanese Patent Office will grant a patent for its unique Cymerus™ MSC technology.
To learn more, read the full press release from Cynata Therapeutics, included below with permission Dr. Ross Macdonald, CEO of Cynata Therapeutics.
Cynata Announces Japanese Patent Office Decision to Grant Patent for Cymerus™ MSC Technology
Melbourne, Australia; 2 May 2016 – Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced that the Japanese Patent and Trademark Office has issued a Decision to Grant a patent covering certain aspects of its proprietary Cymerus™ mesenchymal stem cell (MSC) manufacturing technology. [Read more…]
Cynata Ripe for Global Partnerships as Patent for Cymerus™ MSC Technology Gets Approval in Japan
Cynata Therapeutics, a stem cell and regenerative medicine company listed on the Australian stock exchange (ASX: CYP), released major news today that the Japanese Patent Office will grant a patent for its unique Cymerus™ MSC technology.
Titled “Generation of Clonal Mesenchymal Progenitors and Mesenchymal Stem Cell Lines Under Serum-free Conditions,” the patent covers a proprietary method for deriving MSCs from pluripotent stem cells, to which Cynata Therapeutics with commercial rights in Japan through 2031. [Read more…]
ORIG3N Opens Laboratory and Expanded Headquarters to Support World’s Largest Crowdsourced Biorepository of iPSCs
In major news released today, ORIG3N announced that it has opened a new regenerative medicine laboratory and expanded headquarters in Boston.
Founded in 2014, ORIG3N is creating the world’s largest crowdsourced biorepository of induced pluripotent stem cells (iPSCs) called LifeCapsule™. It uses these blood cells to produce patient-specific iPSCs to grow different cell types, including heart cells (cardiomyocytes), liver cells (hepatocytes), brain cells (neurons), and more.
In addition to collecting donated blood samples for iPSC production, ORIG3N offers an optional LifeCapsule membership, in which individuals can pay $99/year to get permanent access to their own immortalized iPS cells. ORIG3N also has two other business units, LifeProfile and LifeSystems, which are discussed in detail in the interview below.
Learn more by reading the full press release below, printed with permission from Julie Hall, Managing Director of Havas Health and media contact for ORIG3N. [Read more…]
Regulation of the Stem Cell Market is a Tipping Point – Which Way Will It Fall?
The stem cell market has grown increasingly complex over the past few years, especially in the regulatory space. The NIH recently had an overwhelming response for participation in its Part 15 public hearing intended to review “Draft Guidances Relating to the Regulation of Human Cells, Tissues or Cellular or Tissue-Based Products.”
With approximately 600 registrations for the events and 100 people and groups interested in presenting, it was clear that individuals across the United States are concerned about these draft guidances that appear to be a further restriction on stem cell therapy within the U.S. The event has since been rescheduled as a two-day public hearing to be held over September 12-13, 2016, in a larger venue, Masur Auditorium, at the NIH campus in Bethesda, MD. [Read more…]
- « Previous Page
- 1
- …
- 69
- 70
- 71
- 72
- 73
- …
- 79
- Next Page »